

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Cockerill et al

Serial No.:

Examiner:

Filing Date:

Art Unit:

For:

**FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN
TYROSINE KINASE INHIBITORS**

Commissioner for Patents
Washington D.C. 20231

PRELIMINARY AMENDMENT

Sir:

For the purposes of adding the priority information to the continuation application being filed concurrently, please amend the application as follows.

In the Specification:

On the first line of the specification, after the Title, please add:

--This application is a continuation of Serial No. 09/214,267 which is a 35 U.S.C. § 371 United States National Phase Application of PCT/EP97/03672 filed December 31, 1998, which claims priority to GB 9614755.8 filed July 13, 1996 and GB 9625458.6 filed December 7, 1996.--

REMARKS


Applicants have amended the specification for the purpose of adding the priority information. The present application is ready for examination on the merits.

Respectfully submitted,


John L. Lemanowicz
Attorney for Applicants
Registration No. 37,380

Date: 31 January, 2002
GlaxoSmithKline
Five Moore Drive, PO Box 13398
Research Triangle Park
North Carolina 27709
Telephone: (919) 483-8247
Facsimile: (919) 483-7988

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on 1/31/02 in accordance with the provision of 37 CFR §1.8.


Allyson K. Jacobs